---
id: 165
title: BK Polyomavirus (BKPyV)
category: organisms
subcategory: polyomaviruses
tags: [BK-virus, polyomavirus, nephropathy, hemorrhagic-cystitis, transplant, cidofovir, IVIG]
difficulty: medium
---

## Question

What are the key clinical syndromes of BK virus in transplant recipients? Use the **"Kidney: BKPyVAN (Allograft Failure), HSCT: Hemorrhagic Cystitis → Reduce IS, ± Cidofovir/IVIG"** framework.

## Answer

### **BK Polyomavirus (BKPyV) Overview:**

**Epidemiology:**
- **Primary infection:** Childhood (>90% seropositive by adulthood)
- **Latency:** Kidneys, uroepithelium
- **Reactivation:** Immunosuppression (transplant)

### **Clinical Syndromes:**

**BK Polyomavirus-Associated Nephropathy (BKPyVAN) - Kidney Transplant:**

**Presentation:**
- **Allograft dysfunction:** Rising creatinine (mimics rejection)
- **Timing:** 3-12 months post-transplant (median 6 months)
- **Progressive renal failure** if untreated

**Risk Factors:**
- **High-level immunosuppression** (tacrolimus + mycophenolate, antilymphocyte induction)
- **HLA mismatch, acute rejection episodes**

**Diagnosis:**
- **Screening:** Quantitative BK PCR (plasma) every 1-3 months × first 2 years post-transplant
  - **Viremia:** >10,000 copies/mL (high risk for nephropathy)
- **Definitive:** **Kidney biopsy** (gold standard)
  - **Histology:** Tubular injury, viral inclusions (intranuclear, "ground-glass" appearance)
  - **Immunohistochemistry:** SV40 stain (cross-reacts with polyomavirus)
  - **"Decoy cells"** in urine (shed infected uroepithelial cells with viral inclusions)

**Outcomes:**
- **Graft loss:** 10-50% if established nephropathy
- **Early detection + treatment** improves outcomes

**Hemorrhagic Cystitis - Hematopoietic Stem Cell Transplant (HSCT):**

**Presentation:**
- **Gross hematuria** (can be severe)
- **Dysuria, urgency, frequency**
- **Timing:** Weeks to months post-transplant

**Diagnosis:**
- **Urine BK PCR:** High viral load
- **Cystoscopy:** Diffuse mucosal inflammation, ulceration

**Outcomes:**
- **Usually self-limited** (weeks to months)
- **Can be severe** (clot retention, bladder outlet obstruction)

### **Management:**

**BKPyVAN (Kidney Transplant):**

**Primary Strategy: Reduce Immunosuppression:**
- **Decrease CNI (tacrolimus/cyclosporine) by 25-50%**
- **Reduce/stop antimetabolite** (mycophenolate, azathioprine)
- **Goal:** Viral clearance (viral load <10,000 copies/mL)

**Monitor:**
- **Weekly plasma BK PCR** until viral load declining
- **Creatinine** (may transiently worsen with IS reduction due to subclinical rejection risk)
- **Repeat biopsy** if no improvement (rule out concurrent rejection)

**Antiviral Therapy (Limited Efficacy):**
- **NO FDA-approved antivirals** for BK virus
- **Consider if reducing IS fails:**

**Cidofovir:**
- **0.25-1 mg/kg IV weekly** (low-dose to reduce nephrotoxicity)
- **Limited evidence** (case series, conflicting data)
- **Nephrotoxic** (problematic in kidney transplant)

**Leflunomide:**
- **Immunosuppressive + potential antiviral activity**
- **Loading dose:** 100mg PO daily × 3-5 days → **maintenance:** 20-40mg PO daily
- **Mixed evidence** (may help viral clearance)

**Fluoroquinolones:**
- **Ciprofloxacin 500mg PO BID** or **levofloxacin 500mg PO daily**
- **Prophylaxis post-transplant** may reduce BK viremia (controversial)
- **NOT effective for established nephropathy**

**IVIG:**
- **Used in some centers** (provides neutralizing antibodies)
- **Limited evidence**

**Hemorrhagic Cystitis (HSCT):**

**Supportive Care:**
- **Aggressive hydration**
- **Bladder irrigation** (continuous if severe hematuria)
- **Transfusion support** (symptomatic anemia)

**Reduce Immunosuppression:**
- **If feasible** (limited options in HSCT setting)

**Cidofovir:**
- **1 mg/kg IV weekly** (with probenecid + hydration)
- **OR:** **Intravesical cidofovir** (5 mg/mL solution, weekly bladder instillations)
- **Limited evidence**, consider if severe/refractory

**Experimental:**
- **Brincidofovir** (oral lipid conjugate of cidofovir, less nephrotoxic) - compassionate use

## Key Points

### **BKPyVAN = Mimic Rejection:**
- **Rising creatinine** 3-12 months post-kidney transplant
- **Screen with plasma BK PCR** (every 1-3 months × 2 years)
- **Biopsy gold standard** (tubular injury, viral inclusions, SV40 stain)

### **Reduce Immunosuppression = Mainstay:**
- **Decrease CNI by 25-50%**
- **Reduce/stop antimetabolite**
- **Goal:** Viral clearance (<10,000 copies/mL)
- **Risk:** Rejection (monitor closely)

### **"Decoy Cells":**
- **Infected uroepithelial cells** with viral inclusions (in urine)
- **Suggests BK virus replication** (not specific for nephropathy)

### **NO Proven Antivirals:**
- **Cidofovir, leflunomide, IVIG** used empirically (limited evidence)
- **Cidofovir nephrotoxic** (problematic in kidney transplant)
- **Reducing IS most effective**

### **Hemorrhagic Cystitis Self-Limited:**
- **HSCT recipients**
- **Supportive care** (hydration, irrigation, transfusion)
- **Consider cidofovir** if severe (IV or intravesical)

### **Fluoroquinolone Prophylaxis:**
- **May reduce BK viremia** post-kidney transplant (controversial)
- **NOT effective** for established nephropathy

### **Clinical Pearls:**
- **BKPyVAN:** Rising creatinine post-kidney transplant → screen with plasma BK PCR → biopsy if viremia >10,000 copies/mL
- **Reduce IS** = primary treatment (decrease CNI 25-50%, stop antimetabolite)
- **Hemorrhagic cystitis:** HSCT, gross hematuria → supportive care ± cidofovir if severe
- **"Decoy cells"** in urine = BK replication
- **NO proven antivirals** (cidofovir/leflunomide/IVIG empirically used)

## Sources

- [AST: BK Virus in Kidney Transplant 2024]
- [KDIGO: BKPyVAN Guidelines 2024]

## Media

N/A
